Alemtuzumab
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Alemtuzumab
Alemtuzumab
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Alemtuzumab, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own known uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| Known uses recorded for this drug | 2 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| multiple sclerosis | Licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| relapsing-remitting multiple sclerosis |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10228H | Lemtrada | Solution concentrate for I.V. infusion 1 | Valid |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interacting drugs. Examples include:
- Major: deferiprone and samarium (153Sm) lexidronam.
- Moderate: systemic corticosteroids (hydrocortisone, betamethasone, budesonide, dexamethasone, prednisolone, prednisone, triamcinolone), acetylsalicylic acid, anticoagulants (heparin, argatroban, lepirudin), radiopharmaceuticals (ibritumomab tiuxetan, tositumomab, iobenguane I-131, strontium-89) and palifermin.
- Infection and lymphoproliferative risk: The literature compiled for this report describes infectious toxicity with alemtuzumab (PMID 15590388) and an EBV-positive lymphoproliferative disorder after alemtuzumab-containing therapy (PMID 18502831). These are reports from combination regimens, so causality cannot be attributed to alemtuzumab alone.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as these were not available in the data compiled for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.